anti-LRP4 | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

19,403 results for “anti-LRP4”

VYVGART Achieves Primary Endpoint in Phase 3 Trial for AChR-Ab Seronegative Myasthenia Gravis

Nipocalimab Receives FDA Priority Review for Generalized Myasthenia Gravis Treatment

Myasthenia Gravis Market Set to Reach $10.3 Billion by 2034 Driven by Seven Late-Stage Pipeline Therapies

Johnson & Johnson Launches First Head-to-Head FcRn Blocker Study in Myasthenia Gravis

Shark-Derived VNARs Show Promise in Targeting CD20 for Lymphoma Therapy

Nipocalimab Shows Sustained Disease Control in Adolescents with Generalized Myasthenia Gravis

Ipilimumab and Nivolumab Show Promise in Treating Rare Desmoid Tumors

Anti-CXCR4 and Anti-PD-1 Combination Shows Promise in Liver Cancer Treatment

Rentosertib Shifts Six Proteomic Aging Clocks in Phase 2a IPF Substudy, but Cannot Separate Anti-Aging From Anti-Fibrotic Effects

Lasofoxifene Enhances Immunotherapy Efficacy by Promoting Antitumor Activity

Page 1 of 584